
SAN FRANCISCO — A higher proportion of patients with severe, uncontrolled asthma treated with tezepelumab achieved on-treatment clinical response compared with patients treated with placebo, according to a new NAVIGATOR study analysis.
Nearly half of patients achieved complete response to treatment across measures of asthma exacerbation reduction, asthma control, lung function and clinician assessment, Njira L. Lugogo, MD, associate professor of internal medicine, medical director of the Michigan Clinical Research Unit and director of the asthma program in the division of pulmonary and